Of relevance for our work, ERK5 inhibitors sensitize tumor xenografts to standard chemotherapics such as 5-fluorouracil [57], doxorubicin [58], paclitaxel [16] or docetaxel [59], potentiating the intrinsic apoptosis exerted by chemotherapy treatments. The gene discussed is MAPK7; the disease is neoplasm.